{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7414,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de076-6089-753f-9bf9-c30653c46927",
      "docSlug": "bbc58ccb580fa7ec818671bdf7686c85",
      "documentTitle": "Nikola | Results Presentation Deck | 17 slides",
      "authorId": "nikola",
      "authorName": "Nikola",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "The slide is a high-quality photograph of the product with the company logo in the bottom right corner.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6089-753f-9bf9-c30653c46927/17",
      "deckHref": "/decks/019de076-6089-753f-9bf9-c30653c46927",
      "deckAnchorHref": "/decks/019de076-6089-753f-9bf9-c30653c46927#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 17,
          "from": 13,
          "beatId": "3b318590-ee22-4164-90da-1b8a608133de",
          "arcName": "Monroe's Motivated Sequence",
          "arcSlug": "monroes-sequence",
          "beatName": "Action",
          "beatSlug": "monroes-sequence-action",
          "evidence": "appendix and additional information slides",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": "https://imgproxy.kitesheet.com/k4vQKZnpZSZF4e02aiAQpjMgtsjgVOgan5Dc1712MY8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iNmNkNmQ1ZTJhMzQ5ZDcwMWJjNmRiMjI5NDZlZDYyMS9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/1",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": "https://imgproxy.kitesheet.com/jDnRf-nsykF_Q1XPPXECJcGOpoQCraeJbhDj6HLhYVI/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iNmNkNmQ1ZTJhMzQ5ZDcwMWJjNmRiMjI5NDZlZDYyMS9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/ow2GCzh7VzqGGhKUQkdZOB3TkQcALT2ujklHya55SQs/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iNmNkNmQ1ZTJhMzQ5ZDcwMWJjNmRiMjI5NDZlZDYyMS9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/GAwCtel7VXmG7Jj8JhEEwpksx3_0ztNwCGAzsLTWscw/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iNmNkNmQ1ZTJhMzQ5ZDcwMWJjNmRiMjI5NDZlZDYyMS9wMDAxLnBuZw"
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "appendix_disclosure",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/2",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "mission",
      "function": "inspire_vision",
      "notes": "The slide uses a visual bracket system to connect the core mission statement to three pillars.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/3",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": "The slide combines a pipeline status update with a corporate vision statement.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/4",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "team_bio",
      "function": "other",
      "notes": "Includes a grid of headshots for the leadership team and lists for board members and advisors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/5",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Uses a Venn diagram to illustrate the intersection of solving for resistance and selectivity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/6",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-6",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 6,
          "from": 6,
          "beatId": "cf0ecf0b-4b0f-4269-9738-798a936fb4d1",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "Slide 6: Solution overview of PRECISELY Targeted Therapies for patients with cancer.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "Uses a visual process flow to contrast standard therapy failure with Nuvalent's mechanism.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/7",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-7",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "5e62d3b3-7d2f-4957-9be3-165db6a30ea2",
          "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions.",
          "position": 0,
          "objective": "What are the consequences of not addressing drug resistance in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 7,
          "from": 7,
          "beatId": "dff327ba-3600-48ab-8981-2c37017cab5b",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "Slide 7: Problem statement on structural innovations designed to overcome drug-resistance due to kinase mutations.",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Uses a visual comparison framework to illustrate the mechanism of action and clinical benefit.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/8",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-8",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "5e62d3b3-7d2f-4957-9be3-165db6a30ea2",
          "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions.",
          "position": 0,
          "objective": "What are the consequences of not addressing drug resistance in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "solution",
      "function": "present_solution",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/9",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-9",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "5e62d3b3-7d2f-4957-9be3-165db6a30ea2",
          "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions.",
          "position": 0,
          "objective": "What are the consequences of not addressing drug resistance in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The table highlights the clinical gap in patients with prior kinase inhibitor treatment, specifically those with G2032R mutations.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/10",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-10",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "5e62d3b3-7d2f-4957-9be3-165db6a30ea2",
          "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions.",
          "position": 0,
          "objective": "What are the consequences of not addressing drug resistance in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 10,
          "from": 10,
          "beatId": "cf20fd65-cc92-446c-a986-52f3ef139fce",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Sizing",
          "beatSlug": null,
          "evidence": "Slide 10: ROS1-positive NSCLC Market Overview.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The table uses a green/white color coding to highlight positive attributes (Yes) versus negative ones (No).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/11",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-11",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "5e62d3b3-7d2f-4957-9be3-165db6a30ea2",
          "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions.",
          "position": 0,
          "objective": "What are the consequences of not addressing drug resistance in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a medical illustration to map specific TRK receptor inhibition side effects to anatomical locations.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/12",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-12",
      "loopMatches": [
        {
          "to": 12,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "5e62d3b3-7d2f-4957-9be3-165db6a30ea2",
          "evidence": "Slides 7-12 discuss the limitations of current treatments and the need for new solutions.",
          "position": 0,
          "objective": "What are the consequences of not addressing drug resistance in cancer treatment?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses dot plots for IC50 values and a bar chart for tumor regression, highlighting NVL-520's performance.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/13",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-13",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a bar chart to show brain penetrance and a grouped bar chart to show selectivity index, highlighting the drug's potential to avoid off-target CNS effects.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/14",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-14",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a side-by-side comparison layout to distinguish between the dose escalation (Phase 1) and the registrational intent (Phase 2) study designs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/15",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-15",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The slide details the transition from the all-treated population to the NSCLC response-evaluable population.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/16",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-16",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The table highlights a heavily pretreated population, with 77% having received 3 or more prior lines of therapy and 71% having received 2 or more prior ROS1 TKIs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/17",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Data as of 13 Sep 22. N=35 patients.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/18",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-18",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The chart displays dose-dependent exposure levels exceeding multiple efficacy thresholds for ROS1 variants in CNS and peripheral tissues.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/19",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-19",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Clinical trial data table showing efficacy metrics for NVL-520 in NSCLC patients.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/20",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-20",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/21",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-21",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart is a swimmer plot, commonly used in oncology to visualize time-to-event data for individual patients.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/22",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-22",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes a spider plot (target lesion change) and a bar chart (allele clearance).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/23",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-23",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes specific patient case study (65-year-old female) and aggregate clinical trial data.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/24",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 24,
          "from": 13,
          "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "testimonial",
      "function": "illustrate_case",
      "notes": "The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/25",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": "Slide 26 of a pitch deck.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/26",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "other",
      "function": "present_solution",
      "notes": "The slide uses a process flow to show the evolution of data from preliminary Phase 1 to updated data shared with the FDA.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/27",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes detailed clinical trial design, cohort definitions, and study objectives.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/28",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
      "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The TPP is presented as a list of key product attributes.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/29",
      "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
      "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-29",
      "loopMatches": [
        {
          "to": 40,
          "from": 29,
          "name": "Jobs To Be Done",
          "slug": "53-jobs-to-be-done",
          "bestFor": "Product innovation, market entry, competitive positioning",
          "matchId": "5bd43550-4e7b-49ae-9310-ece1e67e14d2",
          "evidence": "Slides 29-40 present preclinical and clinical trial results for NVL-655.",
          "position": 1,
          "objective": "How can Nuvalent's therapies address the needs of patients with specific cancer mutations?",
          "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
          "confidence": 0.6,
          "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}